Hidradenitis Suppurativa Clinical Trials

43 recruiting

Hidradenitis Suppurativa Trials at a Glance

58 actively recruiting trials for hidradenitis suppurativa are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 2 with 15 trials, with the heaviest enrollment activity in Miami, Tampa, and Phoenix. Lead sponsors running hidradenitis suppurativa studies include Novartis Pharmaceuticals, Incyte Corporation, and AbbVie.

Browse hidradenitis suppurativa trials by phase

Treatments under study

About Hidradenitis Suppurativa Clinical Trials

Looking for clinical trials for Hidradenitis Suppurativa? There are currently 43 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hidradenitis Suppurativa trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hidradenitis Suppurativa clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 58 trials

Recruiting
Phase 1

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Hidradenitis SuppurativaPsoriatic ArthritisAxial Spondyloarthritis+1 more
UCB Biopharma SRL20 enrolled12 locationsNCT06888193
Recruiting
Phase 2

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

Hidradenitis Suppurativa
Pfizer240 enrolled54 locationsNCT07228390
Recruiting

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Hidradenitis Suppurativa
University of California, San Francisco3,000 enrolled1 locationNCT04115566
Recruiting
Phase 2

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Sinocelltech Ltd.60 enrolled1 locationNCT07244510
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa
Sanofi144 enrolled43 locationsNCT07225569
Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Hidradenitis Suppurativa
Novartis Pharmaceuticals250 enrolled8 locationsNCT07543419
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Hidradenitis Suppurativa
Incyte Corporation550 enrolled101 locationsNCT06959225
Recruiting

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Rheumatoid Arthritis (RA)Hidradenitis Suppurativa (HS)
Sonoma Biotherapeutics, Inc.36 enrolled10 locationsNCT07123038
Recruiting

Real-world Secukinumab Outcomes in Canadian HS Patients

Hidradenitis Suppurativa
Novartis Pharmaceuticals142 enrolled11 locationsNCT07282015
Recruiting
Phase 3

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled316 locationsNCT06855498
Recruiting
Phase 2

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa
Sanofi208 enrolled69 locationsNCT07170917
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Hidradenitis Suppurativa
Incyte Corporation550 enrolled107 locationsNCT06958211
Recruiting
Phase 2

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Incyte Corporation40 enrolled27 locationsNCT07213973
Recruiting
Phase 1

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa
Incyte Corporation24 enrolled24 locationsNCT07049575
Recruiting
Not Applicable

Aviclear for Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa
University of Miami8 enrolled1 locationNCT06801795
Recruiting
Phase 2Phase 3

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)
Bluefin Biomedicine, Inc.210 enrolled33 locationsNCT07287644
Recruiting
Phase 3

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa
UCB Biopharma SRL40 enrolled18 locationsNCT06921850
Recruiting

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

Atopic DermatitisHidradenitis SuppurativaAcne+3 more
Innovaderm Research Inc.500 enrolled1 locationNCT05994976
Recruiting
Phase 2

A Study With CIT-013 in HS Patients

Hidradenitis Suppurativa (HS)
Citryll BV96 enrolled24 locationsNCT06993233
Recruiting
Phase 3

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa
AbbVie1,280 enrolled279 locationsNCT06468228